2022
Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
Schoenfeld J, Cohen E, Nutting C, Licitra L, Burtness B, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Bourhis J. Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e20-e21. DOI: 10.1016/j.ijrobp.2021.12.046.Peer-Reviewed Original ResearchProgression-free survivalConcurrent CRTConcurrent chemoradiotherapyEvent-free survivalOverall survivalEFS eventsLA-SCCHNAdvanced squamous cell carcinomaRandomized phase 2 studyDefinitive concurrent chemoradiotherapyECOG PS 0T cell-dependent pathwayLocoregional control rateObjective response ratePhase 2 studyPhase 3 trialPlatinum-based chemotherapyHealth-related qualitySquamous cell carcinomaStandard concurrent chemoradiotherapyBiomarkers of responseStandard of careThree-year followIntensity-modulated radiotherapyExposure-response relationship
2021
Resilience to Suicidal Ideation among U.S. Military Veterans with Posttraumatic Stress: Results from the National Health and Resilience in Veterans Study
Kumar S, Hein C, DiLillo D, Pietrzak R. Resilience to Suicidal Ideation among U.S. Military Veterans with Posttraumatic Stress: Results from the National Health and Resilience in Veterans Study. Journal Of Military Social Work And Behavioral Health Services 2021, 10: 328-337. PMID: 36393818, PMCID: PMC9642972, DOI: 10.1080/21635781.2021.2015019.Peer-Reviewed Original ResearchPosttraumatic stress symptomsSuicidal ideationSuicidal ideation severityOperation Enduring Freedom/Operation Iraqi Freedom/Operation New DawnIdeation severityThree-year followSevere suicidal ideationMilitary combat veteransExperience higher ratesStrong protective factorU.S. military veteransOperation New DawnNational HealthVeterans StudyPsychological resilienceProtective factorsProtective psychological factorsTreatment effortsMilitary veteransSeverityMP46-03 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: THREE-YEAR FOLLOW-UP
Klotz L, Pavlovich C, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Sedelaar J, Tirkes T, Arora S, Macura K, Costa D, Pantuck A, Bomers J, Clarke G, Staruch R, Eggener S. MP46-03 PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER: THREE-YEAR FOLLOW-UP. Journal Of Urology 2021, 206: e814-e814. DOI: 10.1097/ju.0000000000002067.03.Peer-Reviewed Original ResearchTrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.
Bourhis J, Burtness B, Licitra L, Nutting C, Schoenfeld J, Sarkouh R, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen E. TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer. Journal Of Clinical Oncology 2021, 39: tps6091-tps6091. DOI: 10.1200/jco.2021.39.15_suppl.tps6091.Peer-Reviewed Original ResearchEvent-free survivalEFS eventsConcurrent chemoradiationAdvanced squamous cell carcinomaRandomized phase 2 studyECOG PS 0T cell-dependent pathwayLocoregional control ratePhase 2 studyPhase 3 trialPlatinum-based chemotherapySquamous cell carcinomaBiomarkers of responseStandard of careThree-year followIntensity-modulated radiotherapyExposure-response relationship× ULNBackbone therapyDefinitive chemoradiationEligible patientsLA-SCCHNMonotherapy periodX ULNConcurrent chemoradiotherapy
2017
O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
Dore G, Grebely J, Altice F, Litwin A, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Conway B, Iser D, Huang H, Gendrano I, Kelly M, Hwang P, Robertson M, Wahl J, Barr E, Platt H. O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study. Journal Of Virus Eradication 2017, 3: 8. DOI: 10.1016/s2055-6640(20)30904-3.Peer-Reviewed Original Research427 Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study
Haber B, Gane E, Dore G, Grebely J, Altice F, Litwin A, Dalgard O, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Conway B, Iser D, Huang H, Gendrano I, Kelly M, Hwang P, Robertson M, Wahl J, Barr E, Platt H. 427 Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study. Gastroenterology 2017, 152: s1058-s1059. DOI: 10.1016/s0016-5085(17)33575-8.Peer-Reviewed Original Research
2015
Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up
Souza CF, Doi H, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA, Xu K, Mehran R, Stone GW, Maehara A. Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up. Coronary Artery Disease 2015, 26: 469-475. PMID: 25919902, DOI: 10.1097/mca.0000000000000251.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery DiseaseCoronary VesselsFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPlaque, AtheroscleroticPlatelet Aggregation InhibitorsPredictive Value of TestsProspective StudiesRisk FactorsRupture, SpontaneousStentsTime FactorsTreatment OutcomeUltrasonography, InterventionalWound HealingConceptsST-segment elevation myocardial infarctionPlaque ruptureIntravascular ultrasoundClinical eventsUnstable plaquesLumen compromiseUntreated segmentsAcute Myocardial Infarction trialLong-term clinical outcomesAcute myocardial infarction patientsBaseline intravascular ultrasoundOptimal systemic therapySerial IVUS analysisMyocardial Infarction trialElevation myocardial infarctionInfarct-related arteryMyocardial infarction patientsThree-year followAttenuated plaqueHarmonizing OutcomesNonculprit lesionsSTEMI patientsSystemic therapyClinical outcomesInfarction patients
2012
Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial
Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR, Investigators F. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. Journal Of Endovascular Therapy 2012, 19: 1-9. PMID: 22313193, DOI: 10.1583/11-3627.1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlloysAngioplasty, BalloonArterial Occlusive DiseasesChi-Square DistributionConstriction, PathologicEuropeFemaleFemoral ArteryHumansIntermittent ClaudicationKaplan-Meier EstimateMaleMiddle AgedPopliteal ArteryPredictive Value of TestsProsthesis DesignRadiographyRisk AssessmentRisk FactorsStentsTime FactorsTreatment OutcomeUltrasonography, Doppler, DuplexUnited StatesVascular PatencyConceptsTarget lesion revascularizationBalloon angioplastyAngioplasty groupStent groupProximal popliteal artery lesionsGood long-term resultsNitinol stent implantationProximal popliteal arteryMajor adverse eventsLong-term resultsPopliteal artery lesionsShort-term patencyStent fracture rateThree-year followLesion revascularizationPrimary nitinolWithdrew consentIntermittent claudicationAdverse eventsArtery lesionsFemoropopliteal lesionsMulticenter trialPopliteal arteryPrimary implantationSuperficial femoral
2003
Trends in Discharge Disposition, Mortality, and Service Use Among Long-Stay Psychiatric Patients in the 1990s
Desai MM, Rosenheck RA. Trends in Discharge Disposition, Mortality, and Service Use Among Long-Stay Psychiatric Patients in the 1990s. Psychiatric Services 2003, 54: 542-548. PMID: 12663843, DOI: 10.1176/appi.ps.54.4.542.Peer-Reviewed Original ResearchMeSH KeywordsAffective Disorders, PsychoticAgedBrain DiseasesCensusesCohort StudiesFemaleHealth Facility ClosureHospital MortalityHospitals, VeteransHumansLength of StayMaleMental Health ServicesMiddle AgedPatient DischargePersons with Psychiatric DisordersPsychotic DisordersUnited StatesUnited States Department of Veterans AffairsUtilization ReviewConceptsDischarge dispositionThree-year followService usePrincipal diagnosisPsychiatric patientsVA mental health servicesLong-stay psychiatric patientsLong-stay bedsLong-stay cohortsStay Psychiatric PatientsVA administrative databasesMental health bedsMental health inpatientsLong-term inpatientsVA service useMental health servicesPatient's principal diagnosisMental health systemFiscal year 1991Administrative databasesMortality ratePsychotic disordersHealth servicesPatientsCohort
2000
EARLY CORTICOSTEROID CESSATION AT ONE WEEK FOLLOWING KIDNEY TRANSPLANT UNDER TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESION, THREE-YEAR FOLLOW-UP.
Buell J, Kulkarni S, Grewal H, Kopelan A, Yoshida A, Swanson A, Cronin D, Bruce D, Newell K, Thistlethwaite J, Woodle E. EARLY CORTICOSTEROID CESSATION AT ONE WEEK FOLLOWING KIDNEY TRANSPLANT UNDER TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESION, THREE-YEAR FOLLOW-UP. Transplantation 2000, 69: s134. DOI: 10.1097/00007890-200004271-00088.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply